Advances in RNA sequencing (RNA-seq) technologies that measure the transcriptome of biological samples have revolutionised our ability to understand transcriptional regulatory programs that underpin diseases such as cancer. We recently published singscore - a single-sample, rank-based gene set scoring method which quantifies how concordant the transcriptional profile of individual samples are relative to specific gene sets of interest. Here we demonstrate the application of singscore to investigate transcriptional profiles associated with specific mutations or genetic lesions in acute myeloid leukemia. Using matched genomic and transcriptomic data available through The Cancer Genome Atlas we show that scoring of appropriate signatures can distinguish samples with corresponding mutations, reflecting the ability of these mutations to drive aberrant transcriptional programs involved in leukemogenesis. We believe the singscore method is particularly useful for studying heterogeneity within specific subsets of cancers, and as demonstrated, singscore has the ability to identify samples where alternative mutations/genetic lesions appear to drive transcriptional programs.

• Using singscore to predict mutations in AML from transcriptomic signatures

• Slack: #bioconductor_SingscoreAMLMutations
  • Slack Invite
• https://support.bioconductor.org